Ababax Health is a Digital Health technology company dedicated to developing Digital Drugs that enable tailored, non-invasive digital interventions to unlock and advance mental and physical health. Ababax pools Software-as-a-Drug competencies by uniting multidisciplinary scientists and technology experts to shape the future of medicine. The Ababax founders, Dr. Markus Müschenich and Christian Lautner, have been Founding Investors at Dopavision since 2017.
https://ababax.health
For further information please contact:
Dopavision GmbH
Stefan Zundel
Managing Director
info@dopavision.com
Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
(END) Dow Jones Newswires
July 14, 2021 04:00 ET (08:00 GMT)